

**ESMIT Online Course Fundamentals of Research in Imaging and Theranostics –**
**Part 1: Research Desgin**
**ESMIT**

|              |   |
|--------------|---|
| Facilitators | Elisabeth Guggenberg<br>Luigi Aloj<br>Meltem Ocak<br>Peter Laverman<br>Jane Sosabowski<br>Petra Kolenc<br>Clemens Decristoforo<br>Piotr Garnuszek<br>Renata Mikolajczak<br>Theodosia Maina<br>Mark Konijnenberg<br>Paola Anna Erba<br>Sona Balogova |
|--------------|---|

**Day 1**
**Introduction**

|               |   |    |                          |
|---------------|---|----|--------------------------|
| 14:00 - 14:05 | Welcome and introduction  | 5  | Elisabeth von Guggenberg |
| 14:05 - 14:20 | Session I: Paving the way for the clinical translation of cholecystokinin-2 receptor targeting                    | 15 | Elisabeth von Guggenberg |
| 14:20 - 14:35 | Session II: Strategies for in vitro characterisation: cell line models and experimental design                    | 15 | Luigi Aloj               |
| 14:35 - 14:50 | Session III: Assessment of biological stability of radiometal-labeled peptides, influence of the assay conditions | 15 | Meltem Ocak              |
| 14:50 - 15:05 | Session IV: Biodistribution studies in xenografted mice to find the optimal CCK2R-targeting peptide               | 15 | Peter Laverman           |
| 15:05 - 15:20 | Session V: The role of preclinical imaging in development of CCK-2 targeting peptides                             | 15 | Jane Sosabowski          |
| 15:20 - 15:35 | Session VI: Investigational Medicinal Product Dossier as a key document to proceed towards a clinical trial       | 15 | Petra Kolenc             |
| 15:35         | End of Day 1  |    |                          |

**Day 2**

|               |   |    |                      |
|---------------|---|----|----------------------|
| 14:00 - 14:15 | Session I: The EU regulatory framework for clinical trial translation of radiopharmaceuticals                             | 15 | Clemens Decristoforo |
| 14:15 - 14:30 | Session II: Quality requirements for a peptide precursor for radiopharmaceutical preparations                             | 15 | Piotr Garnuszek      |
| 14:30 - 14:45 | Session III: Pharmaceutical formulation of a radiopharmaceutical for multicenter clinical trial                           | 15 | Renata Mikolajczak   |
| 14:45 - 15:00 | Session IV: Toward clinical translation of [111In]In/[177Lu]Lu-CP04: From mice to patients via a reliable kit formulation | 15 | Theodosia Maina      |
| 15:00 - 15:15 | Session V: Dosimetry models of [111In]In-CP04 in mice and patients, extrapolation between species and towards therapy     | 15 | Mark Konijnenberg    |
| 15:15 - 15:30 | Session VI: Basics of study design for In-CP04  | 15 | Paola Anna Erba      |
| 15:30 - 15:45 | Closing remarks & Wrap up   | 15 | Sona Balogova        |
| 15:45         | Final Self-Assessment   |    |                      |
| 15:45         | End of Day 2  |    |                      |